Perilous Reversal Watch: Intercept Pharmaceuticals (ICPT)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Intercept Pharmaceuticals ( ICPT) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Intercept Pharmaceuticals as such a stock due to the following factors:

  • ICPT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $308.7 million.
  • ICPT has traded 109,288 shares today.
  • ICPT is down 3.3% today.
  • ICPT was up 11.2% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ICPT with the Ticky from Trade-Ideas. See the FREE profile for ICPT NOW at Trade-Ideas

More details on ICPT:

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. ICPT has a PE ratio of 51.9. Currently there are 5 analysts that rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Intercept Pharmaceuticals has been 550,700 shares per day over the past 30 days. Intercept has a market cap of $5.8 billion and is part of the health care sector and drugs industry. The stock has a beta of -3.22 and a short float of 9.9% with 0.77 days to cover. Shares are up 350.5% year-to-date as of the close of trading on Wednesday.

If you liked this article you might like

Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Clovis Sell-Off May Be Overdone